


Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound CGRP antagonists of general the formula



wherein

A denotes an oxygen or sulphur atom, a phenylsulphonylimino or cyanimino group,

X denotes an oxygen or sulphur atom, an imino group optionally substituted by a C₁₋₆-alkyl group or a methylene group optionally substituted by a C₁₋₆-alkyl group,

U denotes a C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl group wherein each methylene group may be substituted by up to 2 fluorine atoms and each methyl group may be substituted by up to 3 fluorine atoms,

V denotes a chlorine or bromine atom, an amino, methylamino or hydroxy group,

W denotes a hydrogen, fluorine, chlorine, bromine or iodine atom, a difluoro- or trifluoromethyl group,

Amendment dated December 21, 2006

Reply to Office action of June 28, 2006

R¹ denotes a saturated, mono- or diunsaturated 5- to 7-membered aza, diaza, triaza, oxaza, thiaza, thiadiazza or S,S-dioxido-thiadiazza heterocyclic group,

in which the abovementioned heterocycles are linked via a carbon or nitrogen atom,

contain one or two carbonyl or thiocarbonyl groups adjacent to a nitrogen atom,

may be substituted at one of the nitrogen atoms by an alkyl group,

may be substituted at one or at two carbon atoms by an alkyl group, by a phenyl, phenylmethyl, naphthyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl, 1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl group, while the substituents may be identical or different, and

while an olefinic double bond of one of the abovementioned unsaturated heterocycles may be fused to a phenyl, naphthyl, pyridine, diazine, 1,3-oxazole, thienyl, furan, thiazole, pyrrole, N-methylpyrrole or quinoline ring, to a 1H-quinolin-2-one ring optionally substituted at the nitrogen atom by an alkyl group or to an imidazole or N-methylimidazole ring or also two olefinic double bonds of one of the abovementioned unsaturated heterocycles may each be fused to a phenyl ring,

while the phenyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl, 1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl groups contained in R¹ as well as benzo-, thieno-, pyrido- and diazino-fused heterocycles in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine, bromine or iodine atoms, by alkyl, alkoxy, nitro, alkylthio, alkylsulphanyl, alkylsulphonyl, alkylsulphonylamino, phenyl, difluoromethyl, trifluoromethyl, alkoxycarbonyl, carboxy, hydroxy, amino, alkyl-amino, dialkylamino, acetyl, acetylamino, propionylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (4-morpholinyl)carbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-azepinyl)carbonyl,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

(4-methyl-1-piperazinyl)carbonyl, methylenedioxy, aminocarbonylamino, alkanoyl, cyano, difluoromethoxy, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, while the substituents may be identical or different,

R^2 denotes the hydrogen atom,

a phenylmethyl group or a C_{2-7} -alkyl group which may be substituted in the ω position by a cyclohexyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, alkylamino, dialkylamino, carboxy, alkoxy carbonyl, aminocarbonyl, aminocarbonylamino, acetyl amino, 1-pyrrolidinyl, 1-piperidinyl, 4-(1-piperidinyl)-1-piperidinyl, 4-morpholinyl, hexahydro-1H-1-azepinyl, [bis-(2-hydroxyethyl)]amino, 4-alkyl-1-piperazinyl or 4-(ω -hydroxy C_{2-7} -alkyl)-1-piperazinyl group,


a phenyl or pyridinyl group,

while the abovementioned heterocyclic groups and phenyl groups may additionally be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine, bromine or iodine atoms, by methyl, alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, C_{1-3} -alkylamino, di-(C_{1-3} -alkyl) amino, acetyl amino, aminocarbonyl, cyano, methylsulphonyloxy, difluoromethoxy, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl, trifluoromethylsulphonyl, amino- C_{1-3} -alkyl, C_{1-3} -alkylamino- C_{1-3} -alkyl or di-(C_{1-3} -alkyl) amino- C_{1-3} -alkyl groups and the substituents may be identical or different,

R^2 denotes the hydrogen atom or a C_{1-3} -alkyl group optionally substituted by a phenyl or pyridinyl group,

while the C_{1-3} -alkyl group may be linked to an alkyl group present in R^2 or a phenyl or pyridyl ring present in R^2 and the nitrogen atom to which they are bound, forming a ring, or

R² and R³ together with the enclosed nitrogen atom denote a group of general formula



wherein

Y¹ denotes the carbon atom or, if R⁵ is a pair of free electrons, it may also denote the nitrogen atom,

q and r, if Y¹ denotes the carbon atom, represent the numbers 0, 1 or 2, or

q and r, if Y¹ denotes the nitrogen atom, represent the numbers 1 or 2,

R⁴ denotes the hydrogen atom, an amino, alkylamino, cycloalkylamino, dialkylamino, N-(cycloalkyl)-alkylamino, dicycloalkylamino, hydroxy, alkyl, cycloalkyl, amino-C₂₋₇-alkyl, alkylamino-C₂₋₇-alkyl, dialkylamino-C₂₋₇-alkyl, aminoiminomethyl, alkylcarbonyl, alkylsulphonyl, alkylcarbonylamino, alkylsulphonylamino, N-alkylcarbonyl-N-alkylamino, N-alkylsulphonyl-N-alkylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, cycloalkylaminocarbonylamino, dicycloalkylaminocarbonylamino, phenylaminocarbonylamino, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylaminoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl or carboxyalkyl group,

or, if Y¹ does not denote the nitrogen atom, the carboxy, aminomethyl, alkylaminomethyl or dialkylaminomethyl group,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

a phenyl, phenyl-C₁₋₃-alkyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl, pyridinylcarbonyl or phenylcarbonyl group which may each be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine, bromine or iodine atoms, by alkyl, alkoxy, methylsulphonyloxy, difluoromethyl, trifluoromethyl, hydroxy, amino, acetylarnino, aminocarbonyl, aminocarbonylamino, aminocarbonylaminomethyl, cyano, carboxy, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, alkanoyl, ω-(dialkylamino)alkanoyl, ω-(dialkylamino)alkyl, ω-(dialkylamino)hydroxyalkyl, ω-(carboxy)alkanoyl, difluoromethoxy, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, while the substituents may be identical or different,

a saturated or mono- or polyunsaturated 4- to 10-membered azacycloalkyl group, a 5- to 10-membered oxaza-, thiaza, diaza- or triazacycloalkyl group, a 6- to 10-membered azabicyclo- or diazabicycloalkyl group, a 1-alkyl-4-piperidinylcarbonyl or 4-alkyl-1-piperazinylcarbonyl, a 1-alkyl-4-piperidinylamino, 1-alkyl-4-piperidinylaminocarbonyl or 1-alkyl-4-piperidinylaminosulphonyl group,

while the abovementioned mono- and bicyclic heterocycles are bound via a nitrogen or carbon atom,

a methylene group in the abovementioned mono- and bicyclic heterocycles may be replaced by a carbonyl or sulphonyl group,

in the abovementioned mono- and bicyclic heterocycles any methylene group not directly bound to a nitrogen, oxygen or sulphur atom may be substituted by one or two fluorine atoms,

the abovementioned mono- and bicyclic heterocycles as well as the 1-alkyl-4-piperidinylcarbonyl- and 4-alkyl-1-piperazinylcarbonyl group in the ring may be mono- or polysubstituted by a C₁₋₇-alkyl group and/or

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

monosubstituted by a benzyl, alkanoyl, dialkylamino, phenylcarbonyl, pyridinylcarbonyl, carboxy, carboxyalkanoyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylsulphonyl, cycloalkyl or cycloalkylalkyl group, or substituted by a cycloalkylcarbonyl, azacycloalkylcarbonyl, diazacycloalkylcarbonyl or oxazacycloalkylcarbonyl group optionally alkyl-substituted in the ring,

while the alicyclic moieties contained in these substituents each comprise 3 to 10 ring members and the heteroalicyclic moieties each comprise 4 to 10 ring members and

the phenyl and pyridinyl groups contained in the abovementioned groups may in turn be mono-, di- or trisubstituted by fluorine, chlorine, bromine or iodine atoms, by alkyl, alkoxy, methylsulphonyloxy, difluoromethyl, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, aminocarbonylamino, aminocarbonylaminomethyl, cyano, carboxy, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, alkanoyl, ω -(dialkylamino)alkanoyl, ω -(carboxy)alkanoyl, difluoromethoxy, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphanyl or trifluoromethylsulphonyl groups, while the substituents may be identical or different,

R^5 denotes a hydrogen atom,

a C₁₋₄-alkyl group , while an unbranched alkyl group may be substituted in the ω position by a phenyl, pyridinyl, diazinyl, amino, alkylamino, dialkylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-methyl-1-piperazinyl, 4-morpholinyl or hexahydro-1H-1-azepinyl group,

an alkoxycarbonyl, the cyano or aminocarbonyl group or also, if Y¹ denotes a nitrogen atom, a pair of free electrons,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

or, if Y¹ does not denote a nitrogen atom, also the fluorine atom, or

R⁴ and R⁵ together, if Y¹ denotes the carbon atom, denote a 4- to 7-membered cycloaliphatic ring in which one or two methylene groups may be replaced by an -NH- or -N(alkyl)- group and one or two additional methylene groups may be replaced by carbonyl groups,

while a hydrogen atom bound to a nitrogen atom within the abovementioned group R⁴ may be replaced by a protecting group,

R⁶ and R⁷, which may be identical or different, in each case denote a hydrogen atom, a C₁₋₃-alkyl or dialkylamino group or also, if Y¹ does not denote a nitrogen atom, the fluorine atom and

R⁸ and R⁹, which may be identical or different, each denote a hydrogen atom or a C₁₋₃-alkyl, carboxy or C₁₋₃-alkoxycarbonyl group,

while, unless otherwise stated, all the abovementioned alkyl and alkoxy groups as well as the alkyl groups present within the other groups specified comprise 1 to 7 carbon atoms and may be straight-chain or branched, while each methylene group may be substituted by up to 2 fluorine atoms and each methyl group may be substituted by up to 3 fluorine atoms,

all the abovementioned cycloalkyl groups as well as the cycloalkyl groups present within the other groups specified, unless otherwise stated, may comprise 3 to 10 carbon atoms, while each methylene group may be substituted by up to 2 fluorine atoms,

all the abovementioned aromatic and heteroaromatic groups may additionally be mono- di- or trisubstituted by fluorine, chlorine or bromine atoms, by cyano or hydroxy groups and the substituents may be identical or different,

~~the tautomers, diastereomers, enantiomers, hydrates, mixtures thereof and the salts thereof as~~

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

well as the hydrates of the salts or a tautomer, diastereomer, enantiomer or hydrate thereof, or a salt thereof or a hydrate of a salt thereof.

Claim 2 (currently amended): A compound Compounds of general the formula (I) according to claim 1, wherein

A, U, V, W, X, R² and R³ are defined as in claim 1 and

R¹ denotes a mono- or diunsaturated 5- to 7-membered aza, diaza, triaza or thiaza heterocyclic group,

in which the abovementioned heterocycles are linked via a carbon or nitrogen atom,

contain one or two carbonyl groups adjacent to a nitrogen atom,

may be substituted at a carbon atom by a phenyl, pyridinyl, diazinyl, thienyl, pyrrolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl or 1-methylpyrazolyl group and

an olefinic double bond of one of the abovementioned unsaturated heterocycles may be fused to a phenyl, naphthyl, pyridine, diazine, thienyl or quinoline ring or to a 1H-quinolin-2-one ring optionally substituted at the nitrogen atom by a methyl group,

while the phenyl, pyridinyl, diazinyl, thienyl, pyrrolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl or 1-methylpyrazolyl groups contained in R¹ as well as the benzo-, pyrido- and diazino-fused heterocycles in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine, bromine or iodine atoms, by alkyl, alkoxy, nitro, difluoromethyl, trifluoromethyl, hydroxy, amino, alkylamino, dialkylamino, acetylamino, acetyl, cyano, difluoromethoxy or trifluoromethoxy groups, while the substituents may be identical or different,

while the abovementioned alkyl groups or the alkyl groups contained in the abovementioned

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

groups, unless otherwise stated, contain 1 to 7 carbon atoms and may be branched or unbranched, while each methylene group may be substituted by up to 2 fluorine atoms and each methyl group may be substituted by up to 3 fluorine atoms, and

the abovementioned aromatic and heteroaromatic groups may additionally be mono- di- or trisubstituted by fluorine, chlorine or bromine atoms or by cyano or hydroxy groups and the substituents may be identical or different,

~~the tautomers, diastereomers, enantiomers, mixtures thereof and the salts thereof or a tautomer, diastereomer, enantiomer or salt thereof.~~

Claim 3 (currently amended): A compound Compounds of general the formula (I) according to claim 1, wherein

A, U, V, W, X, R² and R³ are defined as in claim 1 and

R¹ denotes a monounsaturated 5- to 7-membered diaza or triaza heterocyclic group,

while the abovementioned heterocycles are linked via a nitrogen atom,

contain a carbonyl group adjacent to a nitrogen atom and

may additionally be substituted at a carbon atom by a phenyl group,

and while an olefinic double bond of one of the abovementioned unsaturated heterocycles may be fused to a phenyl, thienyl or quinoline ring,

while the phenyl groups contained in R¹ as well as benzo-fused heterocycles in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine, bromine or iodine atoms, by methyl, methoxy, nitro, difluoromethyl, trifluoromethyl, hydroxy, amino, alkylamino, dialkylamino, acetylamino, acetyl,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

cyano, difluoromethoxy or trifluoromethoxy groups, while the substituents may be identical or different, but are preferably unsubstituted, or monosubstituted by a fluorine, chlorine or bromine atom or by a methyl or methoxy group,

while, unless otherwise stated, all the abovementioned alkyl groups as well as the alkyl groups present within the other groups comprise 1 to 7 carbon atoms and may be straight-chain or branched and the abovementioned aromatic and heteroaromatic groups may additionally be mono- di- or trisubstituted by fluorine, chlorine or bromine atoms or by cyano or hydroxy groups and the substituents may be identical or different,

the tautomers, diastereomers, enantiomers, mixtures thereof and the salts thereof or a tautomer, diastereomer, enantiomer or salt thereof.

Claim 4 (currently amended): A compound Compounds of general the formula (I) according to claim 1, wherein

A, U, V, W, X, R² and R³ are defined as in claim 1 and

R¹ denotes a 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl, 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl, 4-(5-oxo-3-phenyl-4,5-dihydro-1,2,4-triazol-1-yl)-piperidin-1-yl, 4-(2-oxo-1,2-dihydro-imidazo[4,5-c]quinolin-3-yl)-piperidin-1-yl, 4-(2-oxo-1,2-dihydro-4H-thieno[3,4-d]pyrimidin-3-yl)-piperidin-1-yl, 4-(2-oxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-yl)-piperidin-1-yl, 4-(5-oxo-4,5,7,8-tetrahydro-2-thia-4,6-diaza-azulen-6-yl)-piperidin-1-yl, 4-(2-oxo-1,2,4,5-tetrahydro-thieno[3,2-d]-1,3-diazepin-3-yl)-piperidin-1-yl, 4-(2-oxo-1,2,4,5-tetrahydro-thieno[2,3-d]-1,3-diazepin-3-yl)-piperidin-1-yl or 4-(2-oxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl)-piperidin-1-yl group,

while the abovementioned mono- and bicyclic heterocycles in the carbon skeleton may additionally be monosubstituted by a methoxy group,

while the abovementioned aromatic and heteroaromatic groups by fluorine, chlorine or

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

bromine atoms, by cyano or hydroxy groups may additionally be mono- di- or trisubstituted and the substituents may be identical or different,

~~the tautomers, diastereomers, enantiomers, mixtures thereof and the salts thereof or a tautomer, diastereomer, enantiomer or salt thereof.~~

Claim 5 (currently amended): A compound ~~Compounds~~ of general ~~the~~ formula (I) according to claim 1, wherein

A, U, V, W, X and R¹ are defined as in claim 1 and

R² denotes the hydrogen atom or

a phenylmethyl group or a C₂₋₇-alkyl group which may be substituted in the ω position by a phenyl, pyridinyl, hydroxy, amino, alkylamino, dialkylamino, carboxy, alkoxy carbonyl, aminocarbonyl, aminocarbonylamino, acetyl amine, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, [bis (2-hydroxyethyl)]amino group


while the abovementioned heterocyclic groups and phenyl groups may additionally be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine, bromine or iodine atoms, by methyl, alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl) amino, acetyl amine, aminocarbonyl, cyano, difluoromethoxy, trifluoromethoxy, amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or di-(C₁₋₃-alkyl) amino-C₁₋₃-alkyl groups and the substituents may be identical or different,

R³ denotes the hydrogen atom or a C₁₋₃-alkyl group,

while the C₁₋₃-alkyl group may be linked to an alkyl group present in R² or a phenyl or pyridyl ring present in R² and the nitrogen atom to which they are bound, forming a 5- to 7-membered ring, or

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

R^2 and R^3 together with the enclosed nitrogen atom denote a group of general formula



wherein

Y^1 denotes the carbon atom or, if R^5 denotes a pair of free electrons, it may also denote the nitrogen atom,

q and r , if Y^1 denotes the carbon atom, represent the numbers 0 or 1 or

q and r , if Y^1 denotes the nitrogen atom, represent the numbers 1 or 2,

R^4 denotes the hydrogen atom, a hydroxy, amino, alkylamino, C₃₋₆-cycloalkylamino, N-(C₃₋₆-cycloalkyl)-alkylamino or dialkylamino, an alkyl, trifluoromethyl, C₃₋₆-cycloalkyl, dialkylamino-C₂₋₇-alkyl, carboxyalkyl, alkoxy carbonylalkyl, alkylsulphonyl, alkylsulphonylamino or N-(alkylsulphonyl)-alkylamino group,

or, if Y^1 does not denote the nitrogen atom, it denotes the carboxy or dialkylaminomethyl group,

a phenyl, phenyl-C₁₋₃-alkyl, pyridinyl or diazinyl group each of which may be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethylcarbonyl, methyl or methoxy group,

a saturated or mono- or polyunsaturated 4- to 7-membered azacycloalkyl group, a 5- to 7-membered oxaza-, diaza or triazacycloalkyl group, a 7- to 9-membered azabicyclo or

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

diazabicycloalkyl group, a 1-alkyl-4-piperidinylamino or 1-alkyl-4-piperidinylaminosulphonyl group,

while the abovementioned mono- and bicyclic heterocycles are bound via a nitrogen or carbon atom,

a methylene group of the abovementioned mono- and bicyclic heterocycles may be replaced by a carbonyl or sulphonyl group,

in the abovementioned mono- and bicyclic heterocycles any methylene group not directly bound to a nitrogen, oxygen or sulphur atom may be substituted by one or two fluorine atoms,

the abovementioned mono- and bicyclic heterocycles may be substituted by one or two C₁₋₃-alkyl groups wherein each methylene group may be substituted by up to 2 fluorine atoms and each methyl group may be substituted by up to 3 fluorine atoms, and/or

by a C₃₋₆-cycloalkyl-C₁₋₃-alkyl, benzyl, C₁₋₄-alkanoyl, di-(C₁₋₃-alkyl)-amino or C₁₋₃-alkylsulphonyl, by an alkoxy carbonyl, benzyloxycarbonyl, alkoxy carbonyl alkyl, carboxy or carboxy alkyl group,

R⁵ denotes a hydrogen atom, a C₁₋₃-alkyl or alkoxy carbonyl group or,

if Y¹ denotes a nitrogen atom, it may also denote a pair of free electrons, or

R⁴ and R⁵ together, if Y¹ denotes the carbon atom, represent a 5- to 6-membered cycloaliphatic ring in which one or two methylene groups may be replaced by a -NH- or -N(methyl)- group and one or two further methylene groups may be replaced by carbonyl groups,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

R⁶ and R⁷, which may be identical or different, in each case denote a hydrogen atom or a C₁₋₃-alkyl or di-(C₁₋₃-alkyl)-amino group and

R⁸ and R⁹, which may be identical or different, in each case denote a hydrogen atom or a C₁₋₃-alkyl, carboxy or C₁₋₃-alkoxycarbonyl group,

while, unless otherwise stated, all the abovementioned alkyl groups as well as the alkyl groups present within the other groups comprise 1 to 7 carbon atoms and may be straight-chain or branched and the abovementioned aromatic and heteroaromatic groups may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms or by cyano or hydroxy groups and the substituents may be identical or different,

the tautomers, diastereomers, enantiomers, mixtures thereof and the salts thereof or a tautomer, diastereomer, enantiomer or salt thereof.

Claim 6 (currently amended): A compound ~~Compounds of general~~ ~~the~~ formula (I) according to claim 1, wherein

A, U, V, W, X and R¹ are defined as in claim 1 and

R² denotes a phenylmethyl group or a C₂₋₇-alkyl group which may be substituted in the ω position by a phenyl, amino, alkylamino or dialkylamino group,


~~while the abovementioned phenyl group may be substituted by an amino C₁₋₃-alkyl, C₁₋₃-alkylamino C₁₋₃-alkyl or di-(C₁₋₃-alkyl)-amino C₁₋₃-alkyl group, or~~

R² denotes the hydrogen atom or a C₁₋₃-alkyl group,

R² and R³ together with the nitrogen atom to which they are bound denote a 7-dimethylaminomethyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl or 2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl group or

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

R^2 and R^3 together with the enclosed nitrogen atom denote a group of general formula



wherein

Y^1 denotes the carbon atom or, if R^5 denotes a pair of free electrons, it may also denote the nitrogen atom,

q and r , if Y^1 denotes the carbon atom, represent the numbers 0 or 1 or

q and r , if Y^1 denotes the nitrogen atom, represent the numbers 1 or 2,

R^4 denotes the hydrogen atom,

a phenyl, benzyl or pyridinyl group which may be substituted in each case by a fluorine, chlorine or bromine atom, by a trifluoromethylcarbonyl, methyl or methoxy group,

a hydroxy, carboxy, methyl, trifluoromethyl, n-propyl, phenyl, p-tolyl, p-trifluoromethylcarbonyl-phenyl, p-(3-dimethylaminopropyl)-phenyl, amino, benzyl, tert-butylamino, dimethylamino, diethylamino, diethylaminomethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, 5-aminopentyl, methoxycarbonyl, methoxycarbonylmethyl, perhydro-azepin-1-yl, 4-methyl-perhydro-1,4-diazepin-1-yl, 1-methyl-1-piperidinyl-4-yl, 4-piperazin-1-yl, 4-acetyl-piperazin-1-yl, 4-cyclopropylmethyl-piperazin-1-yl, pyrrolidin-1-yl, 4-ethyl-piperazin-1-yl, 4-isopropyl-piperazin-1-yl, piperidin-1-yl, piperidin-4-yl, morpholin-4-yl, 4,4-difluoro-1-piperidin-1-

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

yl, 1-methyl-1-aza-bicyclo[3.2.1]oct-4-yl, 4-methyl-piperazin-1-yl, 4-ethylpiperazin-1-yl, 1-methyl-piperidin-1-yl, 4-carboxymethyl-piperazin-1-yl, 1-carboxymethyl-piperidin-4-yl, 4-benzyloxycarbonyl-piperazin-1-yl, 1-ethoxycarbonylmethyl-piperidin-4-yl, azetidin-1-yl, 5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl, 1-benzyl-piperidin-4-yl, 4-benzyl-piperazin-1-yl, 4-dimethylaminomethyl-1-phenyl, 2,2,2-trifluoroethyl-piperazin-1-yl, 1-methylsulphonyl-piperidin-4-yl, piperidin-1-yl-methyl, 1-methyl-piperidin-4-yl-amino, methylsulphonylamino, N-methylsulphonyl-N-methylamino, N-(cyclopentyl)-methylamino, 1,1-dioxo- λ^6 -isothiazolidin-2-yl, 2-oxo-perhydro-1,3-oxazin-3-yl, cyclohexyl, 2-oxo-imidazolidin-1-yl, 2-methyl-imidazol-1-yl, 4-methyl-imidazol-1-yl, 4-thiazol-2-yl, 2,4-dimethyl-imidazol-1-yl, 4-imidazol-1-yl, 1,2,4-triazol-1-yl, 1-aza-bicyclo[2.2.2]oct-3-yl, 1-methyl-piperidin-4-yl-methylsulphonyl, 1H-imidazol-4-yl, 4-ethoxycarbonylmethyl-piperazin-1-yl, 1-ethoxycarbonyl-piperidin-4-yl, 4-tert-butoxycarbonylmethyl-piperazin-1-yl, 1-(2,2,2-trifluoroethyl)-piperidin-4-yl, 4-methylsulphonyl-piperazin-1-yl, 2-carboxy-4-methyl-piperazin-1-yl, 3-carboxy-4-methyl-piperazin-1-yl, 2-ethoxycarbonyl-4-methyl-piperazin-1-yl, 3-ethoxycarbonyl-4-methyl-piperazin-1-yl or 4-(2,2,2-trifluoroethyl)-piperazin-1-yl-group,

R⁵ denotes a hydrogen atom, a methyl group or, if Y¹ denotes a nitrogen atom, it may also denote a pair of free electrons, or

R⁴ and R⁵ together, if Y¹ denotes the carbon atom, denote a 1-methyl-piperidin-4-ylidene, cyclohexylidene or imidazolidin-2,4-dion-5-ylidene group,

R⁶ and R⁷ in each case denote a hydrogen atom or a dimethylamino group and

R⁸ and R⁹ in each case denote the hydrogen atom, a carboxy or ethoxycarbonyl group,

while, unless otherwise stated, all the abovementioned alkyl groups as well as the alkyl groups present within the other groups comprise 1 to 7 carbon atoms and may be straight-chain or branched and the abovementioned aromatic and heteroaromatic groups may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by cyano

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

or hydroxy groups and the substituents may be identical or different,

~~the tautomers, diastereomers, enantiomers, mixtures thereof and the salts thereof or a tautomer, diastereomer, enantiomer or salt thereof.~~

Claim 7 (currently amended): A compound Compounds of general the formula (I) according to claim 1, wherein

A denotes an oxygen atom, a cyanoimino or phenylsulphonylimino group,

X denotes an oxygen atom, an imino or methylene group,

U denotes an unbranched C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl group wherein each methylene group may be substituted by up to 2 fluorine atoms and the methyl group may be substituted by up to 3 fluorine atoms,

V denotes an amino or hydroxy group and

W denotes a hydrogen, chlorine or bromine atom or a trifluoromethyl group,

R¹ denotes a monounsaturated 5- to 7-membered diaza- or triaza- heterocyclic group,

while the abovementioned heterocycles are linked via a nitrogen atom,

contain a carbonyl group adjacent to a nitrogen atom,

may additionally be substituted at a carbon atom by a phenyl group and

an olefinic double bond of one of the abovementioned unsaturated heterocycles may be fused to a phenyl, thienyl or quinoline ring,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

while the phenyl groups contained in R¹ as well as benzo-fused heterocycles in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine, bromine or iodine atoms, by methyl, methoxy, nitro, difluoromethyl, trifluoromethyl, hydroxy, amino, alkylamino, dialkylamino, acetylamino, acetyl, cyano, difluoromethoxy or trifluoromethoxy groups, while the substituents may be identical or different, but are preferably unsubstituted or are monosubstituted by a fluorine, chlorine or bromine atom or by a methyl or methoxy group,

R² denotes the hydrogen atom or


a phenylmethyl group or a C₂₋₇ alkyl group which may be substituted in the ω position by a phenyl, pyridinyl, hydroxy, amino, alkylamino, dialkylamino, alkoxy carbonyl, carboxy, aminocarbonyl, aminocarbonylamino, acetylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl or [bis-(2-hydroxyethyl)]amino group,

while the abovementioned heterocyclic groups and phenyl groups may additionally be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine, bromine or iodine atoms, by methyl, alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl) amino, acetylamino, aminocarbonyl, cyano, difluoromethoxy, trifluoromethoxy, amino-C₁₋₃ alkyl, C₁₋₃ alkylamino-C₁₋₃ alkyl or di(C₁₋₃ alkyl) amino-C₁₋₃ alkyl groups and the substituents may be identical or different,

R³ denotes the hydrogen atom or a C₁₋₃ alkyl group,

while the C₁₋₃ alkyl group may be linked to an alkyl group present in R² or a phenyl or pyridyl ring present in R² and the nitrogen atom to which they are bound, forming a 5- to 7-membered ring, or

R² and R³ together with the enclosed nitrogen atom denote a group of general formula



wherein

Y^1 denotes the carbon atom or, if R^5 denotes a pair of free electrons, it may also denote the nitrogen atom,

q and r , if Y^1 denotes the carbon atom, represent the numbers 0 or 1 or

q and r , if Y^1 denotes the nitrogen atom, represent the numbers 1 or 2,

R^4 denotes the hydrogen atom, a hydroxy, amino, alkylamino, C₃₋₆-cycloalkylamino, N-(C₃₋₆-cycloalkyl)-alkylamino or dialkylamino, an alkyl, trifluoromethyl, C₃₋₆-cycloalkyl, dialkylamino-C₂₋₇-alkyl, carboxyalkyl, alkoxy carbonylalkyl, alkylsulphonyl, alkylsulphonylamino or N-(alkylsulphonyl)-alkylamino group,

or, if Y^1 does not denote the nitrogen atom, it denotes the carboxy or dialkylaminomethyl group,

a phenyl, phenyl-C₁₋₃-alkyl, pyridinyl or diazinyl group which may be substituted in each case by a fluorine, chlorine or bromine atom, by a trifluoromethylcarbonyl, methyl or methoxy group,

a saturated or mono- or polyunsaturated 4- to 7-membered azacycloalkyl group, a 5- to 7-membered oxaza-, diaza- or triazacycloalkyl group, a 7- to 9-membered azabicyclo- or diazabicycloalkyl group, a 1-alkyl-4-piperidinylamino or 1-alkyl-4-piperidinylaminosulphonyl group,

while the abovementioned mono- and bicyclic heterocycles are bound via a nitrogen or carbon atom,

a methylene group of the abovementioned mono- and bicyclic heterocycles may be replaced by a carbonyl or sulphonyl group,

in the abovementioned mono- and bicyclic heterocycles any methylene group not directly bound to a nitrogen, oxygen or sulphur atom may be substituted by one or two fluorine atoms,

the abovementioned mono- and bicyclic heterocycles may be substituted by one or two C₁₋₃-alkyl groups, wherein each methylene group may be substituted by up to 2 fluorine atoms and each methyl group may be substituted by up to 3 fluorine atoms, and/or

may be substituted by a C₃₋₆-cycloalkyl-C₁₋₃-alkyl, benzyl, C₁₋₄-alkanoyl, di-(C₁₋₃-alkyl)-amino or C₁₋₃-alkylsulphonyl, by an alkoxy carbonyl, benzyloxycarbonyl, alkoxy carbonyl alkyl, carboxy or carboxy alkyl group,

R⁵ denotes a hydrogen atom, a C₁₋₃-alkyl or alkoxy carbonyl group or,

if Y¹ denotes a nitrogen atom, it may also denote a pair of free electrons, or

R⁴ and R⁵ together, if Y¹ denotes the carbon atom, denote a 5- to 6-membered cycloaliphatic ring wherein one or two methylene groups may be replaced by a -NH- or -N(methyl)- group and one or two further methylene groups may be replaced by one or two carbonyl groups,

R⁶ and R⁷, which may be identical or different, in each case denote the hydrogen atom or a C₁₋₃-alkyl or di-(C₁₋₃-alkyl)-amino group and

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

R⁸ and R⁹, which may be identical or different, in each case denote the hydrogen atom or a C₁₋₃-alkyl, carboxy or C₁₋₃-alkoxycarbonyl group,

while, unless otherwise stated, the abovementioned alkyl groups or the alkyl groups contained in the abovementioned groups contain 1 to 7 carbon atoms and may be branched or unbranched and the abovementioned aromatic and heteroaromatic groups may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by cyano or hydroxy groups and the substituents may be identical or different

the tautomers, diastereomers, enantiomers, mixtures thereof and the salts thereof or a tautomer, diastereomer, enantiomer or salt thereof.

Claim 8 (currently amended). A compound Compounds of general the formula (I) according to claim 1, wherein

A denotes an oxygen atom,

X denotes an oxygen atom, an imino or methylene group,

U denotes a methyl, ethyl, C₂₋₄-alkenyl or C₂₋₄-alkynyl group wherein the methylene group may be substituted by up to 2 fluorine atoms and the methyl group may be substituted by up to 3 fluorine atoms,

V denotes an amino or hydroxy group,

W denotes a hydrogen, chlorine or bromine atom or a trifluoromethyl group,

R¹ denotes a 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl, 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl, 4-(5-oxo-3-phenyl-4,5-dihydro-1,2,4-triazol-1-yl)-piperidin-1-yl, 4-(2-oxo-1,2-dihydro-imidazo[4,5-c]quinolin-3-yl)-piperidin-1-yl, 4-(2-

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

oxo-1,2-dihydro-4H-thieno[3,4-d]pyrimidin-3-yl)-piperidin-1-yl, 4-(2-oxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-yl)-piperidin-1-yl, 4-(5-oxo-4,5,7,8-tetrahydro-2-thia-4,6-diazaazulen-6-yl)-piperidin-1-yl, 4-(2-oxo-1,2,4,5-tetrahydro-thieno[3,2-d]-1,3-diazepin-3-yl)-piperidin-1-yl, 4-(2-oxo-1,2,4,5-tetrahydro-thieno[2,3-d]-1,3-diazepin-3-yl)-piperidin-1-yl or 4-(2-oxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl)-piperidin-1-yl group,

while the abovementioned mono- and bicyclic heterocycles in the carbon skeleton may additionally be monosubstituted by a methoxy group,


~~R² denotes a phenylmethyl group or a C₂₋₇-alkyl group which may be substituted in the ω position by a phenyl, amino, alkylamino or dialkylamino group,~~

~~while the abovementioned phenyl group may be substituted by an amino C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or di(C₁₋₃-alkyl)-amino-C₁₋₃-alkyl group, or~~

~~R² denotes the hydrogen atom or a C₁₋₃-alkyl group,~~

~~R² and R³ together with the nitrogen atom to which they are bound denote a 7-dimethylaminomethyl 1,2,4,5-tetrahydro-3-benzazepin-3-yl or 2-amino 4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl group or~~

R² and R³ together with the enclosed nitrogen atom denote a group of general formula



wherein

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

Y^1 represents the carbon atom or, if R^5 denotes a pair of free electrons, it may also denote the nitrogen atom,

q and r , if Y^1 denotes the carbon atom, represent the numbers 0 or 1 or

q and r , if Y^1 denotes the nitrogen atom, represent the numbers 1 or 2,

R^4 denotes the hydrogen atom,

a phenyl, benzyl or pyridinyl group which may be substituted in each case by a fluorine, chlorine or bromine atom, by a trifluoromethylcarbonyl, methyl or methoxy group,

a hydroxy, carboxy, methyl, trifluoromethyl, n-propyl, phenyl, p-tolyl, p-trifluoromethylcarbonyl-phenyl, p-(3-dimethylaminopropyl)-phenyl, amino, benzyl, tert-butylamino, dimethylamino, diethylamino, diethylaminomethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, 5-aminopentyl, methoxycarbonyl, methoxycarbonylmethyl, perhydro-azepin-1-yl, 4-methyl-perhydro-1,4-diazepin-1-yl, 1-methyl-1-piperidinyl-4-yl, 4-piperazin-1-yl, 4-acetyl-piperazin-1-yl, 4-cyclopropylmethyl-piperazin-1-yl, pyrrolidin-1-yl, 4-ethyl-piperazin-1-yl, 4-isopropyl-piperazin-1-yl, piperidin-1-yl, piperidin-4-yl, morpholin-4-yl, 4,4-difluoro-1-piperidin-1-yl, 1-methyl-1-aza-bicyclo[3.2.1]oct-4-yl, 4-methyl-piperazin-1-yl, 4-ethylpiperazin-1-yl, 1-methyl-piperidin-1-yl, 4-carboxymethyl-piperazin-1-yl, 1-carboxymethyl-piperidin-4-yl, 4-benzyloxycarbonyl-piperazin-1-yl, 1-ethoxycarbonylmethyl-piperidin-4-yl, azetidin-1-yl, 5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl, 1-benzyl-piperidin-4-yl, 4-benzyl-piperazin-1-yl, 4-dimethylaminomethyl-1-phenyl, 2,2,2-trifluoroethyl-piperazin-1-yl, 1-methylsulphonyl-piperidin-4-yl, piperidin-1-yl-methyl, 1-methyl-piperidin-4-yl-amino, methylsulphonylamino, N-methylsulphonyl-N-methylamino, N-(cyclopentyl)-methylamino, 1,1-dioxo- λ^6 -isothiazolidin-2-yl, 2-oxo-perhydro-1,3-oxazin-3-yl, cyclohexyl, 2-oxo-imidazolidin-1-yl, 2-methyl-imidazol-1-yl, 4-methyl-imidazol-1-yl, 4-thiazol-2-yl, 2,4-dimethyl-imidazol-1-yl, 4-imidazol-1-yl, 1,2,4-triazol-1-yl, 1-aza-bicyclo[2.2.2]oct-3-yl, 1-methyl-piperidin-4-yl-methylsulphonyl, 1H-imida-

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

zol-4-yl, 4-ethoxycarbonylmethyl-piperazin-1-yl, 1-ethoxycarbonyl-piperidin-4-yl, 4-tert-butoxycarbonylmethyl-piperazin-1-yl, 1-(2,2,2-trifluoroethyl)-piperidin-4-yl, 4-methylsulphonyl-piperazin-1-yl, 2-carboxy-4-methyl-piperazin-1-yl, 3-carboxy-4-methyl-piperazin-1-yl, 2-ethoxycarbonyl-4-methyl-piperazin-1-yl, 3-ethoxycarbonyl-4-methyl-piperazin-1-yl or 4-(2,2,2-trifluoroethyl)-piperazin-1-yl group,

R⁵ denotes a hydrogen atom, a methyl group or, if Y¹ denotes a nitrogen atom, it may also denote a pair of free electrons, or

R⁴ and R⁵ together, if Y¹ denotes the carbon atom, denote a 1-methyl-piperidin-4-ylidene, cyclohexylidene or imidazolidin-2,4-dion-5-ylidene group,

R⁶ and R⁷ in each case denote a hydrogen atom or a dimethylamino group and

R⁸ and R⁹ in each case denote the hydrogen atom, a carboxy or ethoxycarbonyl group,

while, unless otherwise stated, all the abovementioned alkyl groups as well as the alkyl groups present within the other groups comprise 1 to 7 carbon atoms and may be straight-chain or branched and the abovementioned aromatic and heteroaromatic groups may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms or by cyano or hydroxy groups and the substituents may be identical or different,

the enantiomers, the diastereomers and the salts thereof or a diastereomer, enantiomer or salt thereof.

Claim 9 (currently amended): A compound The following compounds of general the formula (I) according to claim 1, selected from the group consisting of:

- (1) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (2) 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(1'-methyl-[4,4']bipiperidinyl-1-yl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (3) 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (4) 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[1,4']bipiperidinyl-1'-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (5) 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-1-(4-pyridin-4-yl-piperazin-1-yl)-butan-1,4-dione,
- (6) 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(1-methyl-piperidin-4-ylamino)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (7) [4-(1-{2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-piperazin-1-yl]-acetic acid,
- (8) methyl (1'-{2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-[4,4']bipiperidinyl-1-yl)-acetate,
- (9) (1'-{2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-[4,4']bipiperidinyl-1-yl)-acetic acid,
- (10) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-[(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-1,4'-bipiperidinyl-1'-yl-2-oxoethyl]-amide,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (11) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-[(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-dimethylamino-piperidin-1-yl)-2-oxo-ethyl]-amide,
- (12) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-[(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-pyridin-4-yl-piperazin-1-yl)-ethyl]-amide,
- (13) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-[(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-ethyl]-amide,
- (14) benzyl 4-[1-((R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-piperidin-4-yl]-piperazin-1-carboxylate,
- (15) ethyl [1'-(*(R*)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-4,4'-bipiperidinyl-1-yl]-acetate,
- (16) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-*{(R)}*-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide,
- (17) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-*{(R)}*-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl}-amide,
- (18) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-[(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-azetidin-1-yl-piperidin-1-yl)-2-oxo-ethyl]-amide,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (19) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-
{(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(5-methyl-2,5-diaza-
bicyclo[2.2.1]hept-2-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide,
- (20) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-[(R)-
1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-piperazin-1-yl-piperidin-1-
yl)-ethyl]-amide,
- (21) [1'-(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetra-
hydro-1,3-benzodiazepin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl]-4,4'-
bipiperidinyl-1-yl]-acetic acid,
- (22) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-
[1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-1,4'-bipiperidinyl-1'-yl-2-oxo-
ethyl]-amide,
- (23) (S)-2-(4-amino-3-bromo-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-
piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-
yl]-butan-1,4-dione,
- (24) (S)-2-(4-amino-3-bromo-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-
1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-pyridin-4-yl-piperazin-1-yl)-butan-1,4-
dione,
- (25) (S)-2-(4-amino-3-bromo-5-trifluoromethyl-benzyl)-1-1,4'-bipiperidinyl-1'-yl-4-[4-(2-
oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (26) (S)-2-(4-amino-3-bromo-5-trifluoromethyl-benzyl)-1-[4-(1-methyl-piperidin-4-yl)-
piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-
yl]-butan-1,4-dione,

Application No. 10/687,262

Amendment dated December 21, 2006

Reply to Office action of June 28, 2006

- (27) (S)-2-(4-amino-3-bromo-5-trifluoromethyl-benzyl)-1-(1'-methyl-4,4'-bipiperidinyl-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (28) (S)-2-(4-amino-3-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (29) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-dimethylamino-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (30) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(3-dimethylamino-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (31) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-pyrrolidin-1-yl-piperidin-1-yl)-butan-1,4-dione,
- (32) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(1'-methyl-4,4'-bipiperidinyl-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (33) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-cyclopropylmethyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (34) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-morpholine-4-yl-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (35) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-perhydro-azepin-1-yl-piperidin-1-yl)-butan-1,4-dione,
- (36) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-perhydro-1,4-diazepin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (37) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-isopropyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (38) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-1,4'-bipiperidinyl-1'-yl-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (39) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(1-methyl-piperidin-4-yl)-perhydro-1,4-diazepin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (40) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[3-(4-methyl-piperazin-1-yl)-azetidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (41) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(3-pyrrolidin-1-yl-azetidin-1-yl)-butan-1,4-dione,
- (42) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(3-piperidin-1-yl-azetidin-1-yl)-butan-1,4-dione,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (43) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(3-diethylamino-azetidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (44) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-azetidin-1-yl-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (45) (S)-1-[4-(4-acetyl-piperazin-1-yl)-piperidin-1-yl]-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (46) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-diethylaminomethyl-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (47) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-ethyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (48) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(1-ethyl-piperidin-4-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (49) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(3,4,5,6-tetrahydro-2H-4,4'-bipyridinyl-1-yl)-butan-1,4-dione,
- (50) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-pyridin-4-yl-piperazin-1-yl)-butan-1,4-dione,

- (51) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(3-perhydro-azepin-1-yl-azetidin-1-yl)-butan-1,4-dione,
- (52) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(1-benzyl-piperidin-4-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (53) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-benzyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (54) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(7-dimethylaminomethyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (55) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-dimethylaminomethyl-phenyl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (56) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-{4-[4-(2,2,2-trifluoroethyl)-piperazin-1-yl]-piperidin-1-yl}-butan-1,4-dione,
- (57) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(1'-methanesulphonyl-4,4'-bipiperidinyl-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (58) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(9-methyl-3,9-diaza-spiro[5.5]undec-3-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (59) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-piperidin-1-ylmethyl-piperidin-1-yl)-butan-1,4-dione,
- (60) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(2-dimethylaminoethyl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (61) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-N-methyl-N-[2-(1-methylpiperidin-4-yl)ethyl]-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyramide,

- (62) ~~(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-N-methyl-N-(1-methyl-piperidin-4-ylmethyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyramide,~~
- (63) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-piperidin-1-yl-butan-1,4-dione,
- (64) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-propyl-piperidin-1-yl)-butan-1,4-dione,
- (65) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-benzyl-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (66) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(2-diethylaminoethyl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (67) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(3-aza-spiro[5.5]undec-3-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (68) N-(1-{(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-N-methyl-methanesulphonamide,
- (69) N-(1-{(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-methanesulphonamide,
- (70) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(cyclopentyl-methyl-amino)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (71) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-methyl-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (72) methyl (1-{(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-acetate,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (73) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-hydroxy-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (74) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-trifluoromethyl-piperidin-1-yl)-butan-1,4-dione,
- (75) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(1,1-dioxo-1,6-isothiazolidin-2-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (76) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(2-oxo-perhydro-1,3-oxazin-3-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (77) methyl 1-{(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyryl}-piperidine-4-carboxylate,
- (78) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-cyclohexyl-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (79) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-tert-butylamino-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (80) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-phenyl-piperidin-1-yl)-butan-1,4-dione,
- (81) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-p-tolyl-piperidin-1-yl)-butan-1,4-dione,
- (82) 8-{(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyryl}-1,3,8-triaza-spiro[4.5]decan-2,4-dione,
- (83) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(2-oxo-imidazolidin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (84) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-amino-4-methyl-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (85) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (86) (S) 2 (4 amino 3 chloro 5 trifluoromethyl benzyl) 1 (2 amino 4,5,7,8 tetrahydro thiazolo[4,5 d]azepin 6 yl) 4 [4 (2 oxo 1,2,4,5 tetrahydro 1,3 benzodiazepin 3 yl) piperidin 1 yl] butan 1,4 dione,
- (87) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(2-methyl-imidazol-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (88) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-imidazol-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (89) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-thiazol-2-yl-piperazin-1-yl)-butan-1,4-dione,
- (90) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(2,4-dimethyl-imidazol-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (91) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-(4-imidazol-1-yl-piperidin-1-yl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (92) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-1,2,4-triazol-1-yl-piperidin-1-yl)-butan-1,4-dione,
- (93) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(1-aza-bicyclo[2.2.2]oct-3-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (94) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-piperazin-1-yl-butan-1,4-dione,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (95) 4-<{(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyryl}-piperazin-1-sulphonic acid (1-methyl-piperidin-4-yl)-amide,
- (96) (S) 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-N-(5-amino-pentyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyramide,
- (97) (S) 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-N-(3-aminomethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyramide,
- (98) 1-<{(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-carboxylic acid,
- (99) (1-<{(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-acetic acid,
- (100) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (101) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-piperazin-1-yl-piperidin-1-yl)-butan-1,4-dione,
- (102) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(1H-imidazol-4-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (103) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-{4-[4-(2,2,2-trifluoro-acetyl)-phenyl]-piperazin-1-yl}-butan-1,4-dione,
- (104) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (105) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(5-oxo-3-phenyl-4,5-dihydro-1,2,4-triazol-1-yl)-piperidin-1-yl]-butan-1,4-dione,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (106) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2-dihydro-imidazo[4,5-c]quinoline-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (107) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2-dihydro-4H-thieno[3,4-d]pyrimidin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (108) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (109) (S)-2-(4-amino-3,5-bis-trifluoromethyl-benzyl)-1-[4-(4-methyl-perhydro-1,4-diazepin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (110) (S)-2-(4-amino-3,5-bis-trifluoromethyl-benzyl)-1-[4-(1-methyl-piperidin-4-yl)-perhydro-1,4-diazepin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (111) (S)-2-(4-amino-3,5-bis-trifluoromethyl-benzyl)-1-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (112) (S)-2-(4-amino-3,5-bis-trifluoromethyl-benzyl)-1-[4-(1-aza-bicyclo[2.2.2]oct-3-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (113) (S)-2-(4-amino-3,5-bis-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (114) (S)-2-(4-amino-3,5-bis-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-perhydro-azepin-1-yl)-butan-1,4-dione,
- (115) (S)-2-(4-amino-3,5-bis-trifluoromethyl-benzyl)-1-1,4'-bipiperidinyl-1'-yl-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (116) (S)-2-(4-amino-3,5-bis-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-1-(4-piperazin-1-yl)-piperidin-1-yl)-butan-1,4-dione,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (117) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-{(R)-1-(4-amino-3,5-bis-trifluoromethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide,
- (118) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-{(R)-1-(4-amino-3,5-bis-trifluoromethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl}-amide,
- (119) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-[(R)-1-(4-amino-3,5-bis-trifluoromethyl-benzyl)-2-1,4'-bipiperidinyl-1'-yl-2-oxo-ethyl]-amide,
- (120) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid-[(R)-1-(4-amino-3,5-bis-trifluoromethyl-benzyl)-2-oxo-2-(4-piperazin-1-yl-piperidin-1-yl)-ethyl]-amide,
- (121) (R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylate,
- (122) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid [2-[1,4']bipiperidinyl-1'-yl-1-(4-bromo-3-methyl-benzyl)-2-oxo-ethyl]-amide,
- (123) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-[1-(4-bromo-3-methyl-benzyl)-2-(1'-methyl-[4,4']bipiperidinyl-1-yl)-2-oxo-ethyl]-amide,
- (124) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-{1-(4-bromo-3-methyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide,
- (125) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-{1-(4-bromo-3-methyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl}-amide,
- (126) ethyl {4-[1-(3-(4-bromo-3-methyl-phenyl)-2-{{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-piperidin-4-yl]-piperazin-1-yl}-acetate,
- (127) ethyl [1'-(3-(4-bromo-3-methyl-phenyl)-2-{{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-[4,4']bipiperidinyl-1-yl]-acetate,
- (128) ethyl {4-[4-(3-(4-bromo-3-methyl-phenyl)-2-{{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-piperazin-1-yl]-piperidin-1-yl}-acetate,

- (129) {4-[1-(3-(4-bromo-3-methyl-phenyl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-piperidin-4-yl]-piperazin-1-yl}-acetic acid,
- (130) [1'-(3-(4-bromo-3-methyl-phenyl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-[4,4']bipiperidinyl-1-yl]-acetic acid,
- (131) {4-[4-(3-(4-bromo-3-methyl-phenyl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-piperazin-1-yl]-piperidin-1-yl}-acetic acid,
- (132) 2-(4-bromo-3-methyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (133) 2-(4-bromo-3-methyl-benzyl)-1-(1'-methyl-[4,4']bipiperidinyl-1-yl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (134) 1-[1,4']Bipiperidinyl-1'-yl-2-(4-bromo-3-methyl-benzyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (135) 2-(4-bromo-3-methyl-benzyl)-1-{4-[4-(3-dimethylamino-propyl)-phenyl]-piperazin-1-yl}-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (136) [4-(1-{2-(4-bromo-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-piperazin-1-yl]-acetic acid,
- (137) methyl (1'-{2-(4-bromo-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-[4,4']bipiperidinyl-1-yl)-acetate,
- (138) (1'-{2-(4-bromo-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-[4,4']bipiperidinyl-1-yl)-acetic acid,
- (139) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid {1-(4-chloro-3-methyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide,
- (140) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-[2-[1,4']bipiperidinyl-1'-yl-1-(4-chloro-3-methyl-benzyl)-2-oxo-ethyl]-amide,

- (141) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-{1-(4-chloro-3-methyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl}-amide,
- (142) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-[1-(4-chloro-3-methyl-benzyl)-2-(1'-methyl-[4,4']bipiperidinyl-1-yl)-2-oxo-ethyl]-amide,
- (143) ethyl [1'-(3-(4-chloro-3-methyl-phenyl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-[4,4']bipiperidinyl-1-yl]-acetate,
- (144) tert-butyl {4-[1-(3-(4-chloro-3-methyl-phenyl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-piperidin-4-yl]-piperazin-1-yl}-acetate,
- (145) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-{1-(4-chloro-3-methyl-benzyl)-2-oxo-2-[1'-(2,2,2-trifluoro-ethyl)-[4,4']bipiperidinyl-1-yl]-ethyl}-amide,
- (146) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-(1-(4-chloro-3-methyl-benzyl)-2-oxo-2-{4-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-piperidin-1-yl}-ethyl)-amide,
- (147) [1'-(3-(4-chloro-3-methyl-phenyl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carbonyl]-amino}-propionyl)-[4,4']bipiperidinyl-1-yl]-acetic acid,
- (148) 2-(4-chloro-3-methyl-benzyl)-1-[4-(4-ethyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (149) 2-(4-chloro-3-methyl-benzyl)-1-(1'-methyl-[4,4']bipiperidinyl-1-yl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (150) 1-[1,4']Bipiperidinyl-1'-yl-2-(4-chloro-3-methyl-benzyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (151) 2-(4-chloro-3-methyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (152) 2-(4-chloro-3-methyl-benzyl)-1-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,

- (153) 2-(4-chloro-3-methyl-benzyl)-1-[4-(4-methanesulphonyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (154) 2-(4-chloro-3-methyl-benzyl)-1-[4-(4-isopropyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (155) ethyl 1-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-4-(1-methyl-piperidin-4-yl)-piperazin-2-carboxylate,
- (156) ethyl 1-(1-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-4-methyl-piperazin-2-carboxylate,
- (157) ethyl 4-(1-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-1-methyl-piperazin-2-carboxylate,
- (158) ethyl 4-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-1-(1-methyl-piperidin-4-yl)-piperazin-2-carboxylate,
- (159) 2-(4-chloro-3-methyl-benzyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-1-[1'-(2,2,2-trifluoro-ethyl)-[4,4']bipiperidinyl-1-yl]-butan-1,4-dione,
- (160) 2-(4-chloro-3-methyl-benzyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-1-{4-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-piperidin-1-yl}-butan-1,4-dione,
- (161) [4-(1-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-piperazin-1-yl]-acetic acid,
- (162) methyl (1'-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-[4,4']bipiperidinyl-1-yl)-acetate,
- (163) (1'-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-[4,4']bipiperidinyl-1-yl)-acetic acid,
- (164) 1-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-4-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylic acid,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (165) 1-(1-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-4-methyl-piperazine-2-carboxylic acid,
- (166) 4-(1-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-1-methyl-piperazine-2-carboxylic acid,
- (167) 2-(4-chloro-3-methyl-benzyl)-1-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (168) 2-(4-chloro-3-methyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (169) [4-(1-{2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(5-oxo-3-phenyl-4,5-dihydro-1,2,4-triazol-1-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-piperazin-1-yl]-acetic acid,
- (170) methyl (1'-(2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(5-oxo-3-phenyl-4,5-dihydro-1,2,4-triazol-1-yl)-piperidin-1-yl]-butyryl)-4,4'-bipiperidinyl-1-yl)-acetate,
- (171) (1'-(2-(4-chloro-3-methyl-benzyl)-4-oxo-4-[4-(5-oxo-3-phenyl-4,5-dihydro-1,2,4-triazol-1-yl)-piperidin-1-yl]-butyryl)-4,4'-bipiperidinyl-1-yl)-acetic acid,
- (172) 2-(3-bromo-4-chloro-5-methyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (173) 2-(3-bromo-4-chloro-5-methyl-benzyl)-1-(1'-methyl-[4,4']bipiperidinyl-1-yl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (174) 2-(3-bromo-4-chloro-5-methyl-benzyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-1-(4-pyridin-4-yl-piperazin-1-yl)-butan-1,4-dione,
- (175) 2-(3-bromo-4-chloro-5-methyl-benzyl)-1-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,

- (176) [4-(1-{2-(3-bromo-4-chloro-5-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-piperazin-1-yl]-acetic acid,
- (177) methyl (1'-(2-(3-bromo-4-chloro-5-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl)-[4,4']bipiperidinyl-1-yl)-acetate,
- (178) (1'-(2-(3-bromo-4-chloro-5-methyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl)-[4,4']bipiperidinyl-1-yl)-acetic acid,
- (179) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid{1-(3-bromo-4-chloro-5-methyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide,
- (180) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-[2-[1,4']bipiperidinyl-1'-yl-1-(3-bromo-4-chloro-5-methyl-benzyl)-2-oxo-ethyl]-amide,
- (181) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-{1-(3-bromo-4-chloro-5-methyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl}-amide,
- (182) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-[1-(3-bromo-4-chloro-5-methyl-benzyl)-2-(1'-methyl-[4,4']bipiperidinyl-1-yl)-2-oxo-ethyl]-amide,
- (183) 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-carboxylic acid-[1-(3-bromo-4-chloro-5-methyl-benzyl)-2-oxo-2-(4-pyridin-4-yl-piperazin-1-yl)-ethyl]-amide,
- (184) 2-(4-chloro-3-trifluoromethyl-benzyl)-1-(1'-methyl-[4,4']bipiperidinyl-1-yl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (185) 2-(4-chloro-3-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (186) 1-[1,4']Bipiperidinyl-1'-yl-2-(4-chloro-3-trifluoromethyl-benzyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,
- (187) [4-(1-{2-(4-chloro-3-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-piperazin-1-yl]-acetic acid,

Application No. 10/687,262
Amendment dated December 21, 2006
Reply to Office action of June 28, 2006

- (188) methyl (1'-(2-(4-chloro-3-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl)-[4,4']bipiperidinyl-1-yl)-acetate,
- (189) (1'-(2-(4-chloro-3-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl)-[4,4']bipiperidinyl-1-yl)-acetic acid, and
- (190) 2-(4-chloro-3-trifluoromethyl-benzyl)-1-(1'-methyl-[4,4']bipiperidinyl-1-yl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butan-1,4-dione,

~~the enantiomers, the diastereomers and the salts thereof or an enantiomer, diastereomer or salt thereof.~~

Claim 10 (currently amended): A physiologically acceptable salt of a compound according to claim 1 ~~Physiologically acceptable salts of the compounds according to at least one of claims 1 to 9 with inorganic or organic acids or bases inorganic or organic acids or bases.~~

Claim 11 (currently amended): A pharmaceutical composition containing a compound according to claim 1 or a physiologically acceptable salt thereof together with an inert carrier or diluent ~~Pharmaceutical compositions containing a compound according to at least one of claims 1 to 9 or a physiologically acceptable salt according to claim 10 optionally together with one or more inert carriers and/or diluents.~~

Claim 12 (currently amended): A method for treating or reducing the frequency of headache, migraine headache or cluster headache which comprises the administration, to a host currently suffering from a headache, migraine headache or cluster headache, or a host having an increased risk of suffering from a headache, migraine headache or cluster headache, an effective amount of a compound according to claim 1 or a physiologically acceptable salt thereof Use of a compound according to at least one of claims 1 to 10 for preparing a pharmaceutical composition for the acute and prophylactic treatment of headaches, particularly migraine or cluster headaches.

Claims 13-16 (cancelled)